Statin and fibrate combination

This page covers all Statin and fibrate combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HMG-CoA reductase and PPAR-α, HMG-CoA reductase (rosuvastatin); PPAR-α (fenofibrate).

Targets

HMG-CoA reductase and PPAR-α · HMG-CoA reductase (rosuvastatin); PPAR-α (fenofibrate)

Marketed (2)

• Atorvastatin and fenofibrate · The University of Western Australia · Cardiovascular
  This combination reduces blood lipids by inhibiting cholesterol synthesis (atorvastatin) and activating peroxisome proliferator-activated receptors to increase triglyceride clearance (fenofibrate).
• Rosuvastatin and fenofibrate · Gachon University Gil Medical Center · Cardiovascular
  This combination reduces cholesterol and triglycerides by inhibiting HMG-CoA reductase (rosuvastatin) and activating peroxisome proliferator-activated receptors (fenofibrate).

Patent intelligence

• statin and fibrate combination patent landscape — aggregated cliff calendar, attackable patents, originator estates